Main menu
Features
Webinars
Icon Library
Pricing
Testimonials
COVID VacTracker
Sign in
Sign up free

COVID-19 Vaccine & Therapeutics Tracker

See the latest updates for vaccine and therapeutic drug developments for COVID-19. Check back for regular updates!
New addition counters are reset every Monday by 11:59 PM ET. Last updated June 4, 2020 at 6:55 PM ET
Vaccines
139
+2
TOTAL
17
+2
IN HUMAN TRIALS
Therapeutic Drugs
239
+9
TOTAL
147
+9
IN HUMAN TRIALS
Activity FeedLive updates on vaccine and therapeutic drug developments
A new study published in the New England Journal of Medicine indicates that prophylactic (Hydroxy)Chloroquine* did not prevent Covid-19 or confirmed SARS-CoV-2 infection within 4 days After high-risk or moderate-risk exposure.
June 3, 2020
The Brazilian Health Regulatory Agency approves human trials for Oxford University and AstraZeneca's AZD1222 (ChAdOx1 nCoV-19) . 2000 participants will be considered in a study carried out by Oxford University and supported by AstraZeneca.
June 2, 2020
A report released indicates that the Phase 3 clinical trials for Moderna’s COVID-19 experimental vaccine, mRNA-1273 , will start in July with the enrollment of 30,000 individuals in a randomized, placebo-controlled trial.
June 2, 2020
Intravenous Immunoglobulin (IVIG; Octagam) therapy sponsored by Octapharma and Sharp HealthCare enters Phase IV clinical trials for COVID-19.
June 2, 2020
A new Unnamed Inactive Vaccine SARS-CoV-2 vaccine being developed by the Chinese Academy of Medical Sciences in collaboration with West China Second University Hospital and Yunnan Center for Disease Control and Prevention enters Phase 1/2.
June 2, 2020
Results released by Gilead indicate that in a Phase III trial, Remdesivir* treatment resulted in significantly greater clinical improvement versus standard of care treatment alone.
June 1, 2020
The immunosuppressive/antiviral Merimepodib* by ViralClear Pharmaceuticals enters Phase II clinical trials against COVID-19.
June 1, 2020
Emergent BioSolutions enters into a $628 million contract with the US government to boost manufacturing capacity for a COVID-19 vaccine.
June 1, 2020
mRNA-1273 , the joint vaccine initiative by Moderna, NIAID, and BARDA, enters Phase 2 clinical trials for COVID-19.
May 28, 2020
The spike protein subunit vaccine by Clover Biopharmaceutical, SCB-2019 , enters Phase 1 clinical trials against COVID-19.
May 28, 2020
France’s health ministry cancels the usage of (Hydroxy)Chloroquine* as a treatment to patients suffering severe forms of COVID-19.
May 27, 2020
The United Kingdom National Health Service follows suit behind The United States and Japan and authorizes the use of Remdesivir* for people with coronavirus infection after a publication in The New England Journal of Medicine indicates it can cut recovery time by about four days.
May 26, 2020
The World Health Organization suspends testing of (Hydroxy)Chloroquine* as a treatment for coronavirus after publication in The Lancet suggests drug could increase the risk of patients dying from COVID-19.
May 25, 2020
Novavax administrates the NVX-CoV2373 vaccine to the first participants in Phase 1 clinical trial. Phase 2 planned to begin following successful Phase 1 results. On May 11, Novavax secured a $388M grant from CEPI (a Bill & Melinda Gates Foundation-backed vaccine development coalition).
May 25, 2020
Sinovac Biotech Co. has received $15M in funding to advance the development of its Covid-19 vaccine candidate, CoronaVac .
May 25, 2020
CanSino Biologics’ Ad5-nCoV vaccine starts Phase 1/2 clinical trials in Canada against COVID-19 in collaboration with the Canadian Center for Vaccinology.
May 22, 2020
Phase 1 results for CanSino Biologics’ Ad5-nCoV vaccine published in The Lancet indicate it was tolerable and immunogenic in humans and warrants further clinical trials testing.
May 22, 2020
AstraZeneca/The University of Oxford vaccine AZD1222 (ChAdOx1 nCoV-19) starts Phase 2 / 3 clinical trials for COVID-19.
May 22, 2020
The INOPulse Delivery System by Bellerophon Therapeutics enters Phase 2 clinical trials for COVID-19.
May 22, 2020
AZD1222 (ChAdOx1 nCoV-19) , developed by the University of Oxford and licensed to AstraZeneca secures $1.2 billion backing from U.S Department of Health for accelerated development.
May 21, 2020
Publication in Nature Communications demonstrates robust antibody and cellular immunity elicited by Inovio's INO-4800 vaccine in preclinical models.
May 20, 2020
Inovio Pharmaceuticals press release announces positive interim Phase 1 data for their INO-4800 vaccine.
May 20, 2020
The elastase inhibitor MPH996* starts Phase 2 clinical trials for COVID-19 in Egypt.
May 20, 2020
Inovio Pharmaceutical's INO-4800 vaccine elicits robust immune response in preclinical models as shown in Nature Communications publication.
May 20, 2020
The C3 complement inhibitor AMY-101 sponsored by Amyndas Pharmaceuticals starts Phase 2 clinical trials for severe COVID-19.
May 20, 2020
Atea Pharmaceuticals' AT-527 , a novel modified guanosine nucleotide prodrug, starts Phase 2 for COVID-19.
May 20, 2020
ABX464 , a small molecule inhibitor of the cap binding complex sponsored by Abivax enters Phase 2 / 3 clinical trials for COVID-19.
May 19, 2020
Moderna press release announces positive interim Phase 1 data for its mRNA Vaccine, mRNA-1273 .
May 18, 2020
Health Canada approves human testing for CanSino Biologics's Ad5-nCoV vaccine. Trial will be conducted out of the Canadian Centre for Vaccinology at Dalhousie University.
May 18, 2020
EIDD-2801 , an oral nucleoside analog sponored by Ridgeback Biotherapeutics, enters Phase I clinical trials for COVID-19.
May 18, 2020
The Cambridge University Hospitals NHS Foundation Trust-sponsored TACTIC-R study commences, bumping Ravulizumab into Phase 4 clinical trials.
May 18, 2020
The Cambridge University Hospitals NHS Foundation Trust-sponsored TACTIC-R study commences, bumping Baricitinib* into Phase 4 clinical trials.
May 18, 2020
Implicit Bioscience and the University of Washington’s anti-CD14 antibody, IC14 , enters Phase 2 clinical trials for COVID-19.
May 18, 2020
The anti-malarial Artemisinin enters Phase 2 clinical trials for COVID-19.
May 15, 2020
AV-COVID-19 is a new dendritic cell vaccine in Phases 1/2 clinical trials for COVID-19.
May 13, 2020
Ifenprodil , an NDMA inhibitor by Algernon Pharmaceuticals and Novatech starts Phase 2 / 3 clinical trials for COVID-19.
May 11, 2020
The vaccine for tuberculosis, Bacille Calmette-Guerin is now in consideration for COVID-19. Undergoing clinical Phases 3/4 trials.
April 20, 2020
Subscribe to Updates Enter your email to get alerted with major weekly updates.
Email
How would you describe yourself?
Vaccines
Visualized development progress and additional information on preclinical and human clinical vaccine candidates against COVID-19.
139
+2
TOTAL

122 in preclinical development

17 in human trials

Vaccine Candidates Development Progress

Vaccine CANDIDATES

PittCoVacc
CureVac
DPX-COVID-19
AdCOVID
CoroFlu
LUNAR-COV19
+117 unnamed
Preclinical
122
Phase I
15
Phase II
10
Phase III
3
Phase IV
1

Legend

Completed
In trials
Vaccine CandidatesClick on name for additional information
  ↓/↑NameOrganizationTechnology  ↓/↑Stage  Countries  ↓/↑Clinical Trial #
Shenzhen Geno-Immune Medical Institute
Modified APCPhase I/II
China
NCT04276896
updated
Multiple Organizations
RNA-based vaccinePhase I/II
United States of America
NCT04283461
and 1 more
Multiple Organizations
Non-replicating viral vectorPhase I/II
ChinaCanada
NCT04313127
and 4 more
updated
Sinovac Biotech Co.
Inactivated virusPhase I/II
China
NCT04352608
and 1 more
Inovio Pharmaceuticals
DNA-basedPhase I
United States of America
NCT04336410
Beijing Institute of Biological Products,
Wuhan Institute of Biological Products
Inactivated virusPhase I/II
China
ChiCTR2000031809
and 1 more
Multiple Organizations
DNA-basedPhase I
Canada
NCT04334980
Biontech RNA Pharmaceuticals GmbH,
Pfizer
RNA-based vaccinePhase I/II
Germany
EudraCT 2020-001038-36
and 2 more
updated
Novavax
Protein subunitPhase I
United States of AmericaAustralia
NCT04368988
Shenzhen Geno-Immune Medical Institute
Modified APCPhase I
China
NCT04299724
Unnamed
Saiba GmbH
Virus Like ParticlePreclinical Phase
Unnamed
Medicago Inc.
Virus Like ParticlePreclinical Phase
Unnamed
Imophoron Ltd,
Bristol University's Max Planck Centre
Virus Like ParticlePreclinical Phase
Unnamed
Doherty Institute
Virus Like ParticlePreclinical Phase
Unnamed
Catholic University/ Millennium Institute of Immunology and Immunotherapy/ Technological Consortium in Clinical Molecular Biomedicine,
Chile*
UnknownPreclinical Phase
Unnamed
Emergex Vaccines,
George Mason University's National Center for Biodefense and Infectious Diseases (NCBID)*
UnknownPreclinical Phase
Unnamed
VBI Vaccines,
National Research Council of Canada
UnknownPreclinical Phase
Unnamed
SmartPharm Therapeutics,
Sorrento Therapeutics
UnknownPreclinical Phase
Unnamed
HaloVax (Voltron Therapeutics),
The Vaccine & Immunotherapy Center at the Massachusetts General Hospital
UnknownPreclinical Phase
Unnamed
ISR Immune System Regulation
UnknownPreclinical Phase
Unnamed
ImmunoPrecise
UnknownPreclinical Phase
Unnamed
Tulane University
UnknownPreclinical Phase
Unnamed
SK Biosciences
UnknownPreclinical Phase
Unnamed
Vir Biotechnology,
GSK
UnknownPreclinical Phase
Unnamed
Precision Vaccines Program at Boston Children's Hospital
UnknownPreclinical Phase
Unnamed
Kentucky BioProcessing (British American Tobacco)
UnknownPreclinical Phase
Unnamed
Universite Laval
UnknownPreclinical Phase
Unnamed
Covaxx
UnknownPreclinical Phase
UnnamedMultiple Organizations
RNA-based vaccinePreclinical Phase
UnnamedMultiple Organizations
RNA-based vaccinePreclinical Phase
Unnamed
Centro Nacional Biotecnologia (CNB-CSIC),
Spain
RNA-based vaccinePreclinical Phase
Unnamed
University of Tokyo,
Daiichi-Sankyo
RNA-based vaccinePreclinical Phase
UnnamedMultiple Organizations
RNA-based vaccinePreclinical Phase
LUNAR-COV19
Arcturus,
Duke-NUS
RNA-based vaccinePreclinical Phase
United States of AmericaRepublic of Singapore
Unnamed
Imperial College London
RNA-based vaccinePreclinical Phase
CureVac
CureVac
RNA-based vaccinePreclinical Phase
Germany
UnnamedMultiple Organizations
RNA-based vaccinePreclinical Phase
Unnamed
BIOCAD
RNA-based vaccinePreclinical Phase
Unnamed
Sanofi Pasteur,
Translate Bio
RNA-based vaccinePreclinical Phase
UnnamedMultiple Organizations
RNA-based vaccinePreclinical Phase
Unnamed
GeneOne Life Science,
Houston Methodist
RNA-based vaccinePreclinical Phase
Unnamed
Zydus Cadila
Replicating viral vectorPreclinical Phase
UnnamedMultiple Organizations
Replicating viral vectorPreclinical Phase
UnnamedMultiple Organizations
Protein subunitPreclinical Phase
Unnamed
ExpreS2ion
Protein subunitPreclinical Phase
Unnamed
WRAIR,
USAMRIID
Protein subunitPreclinical Phase
Unnamed
National Institute of Infectious Disease,
Japan
Protein subunitPreclinical Phase
Unnamed
Osaka University / BIKEN / National Institutes of Biomedical Innovation,
Japan
Protein subunitPreclinical Phase
new
Clover Biopharmaceuticals
Protein subunitPhase I
China
NCT04405908
Unnamed
Vaxil Bio
Protein subunitPreclinical Phase
Unnamed
Biological E Ltd
Protein subunitPreclinical Phase
Unnamed
AJ Vaccines
Protein subunitPreclinical Phase
UnnamedMultiple Organizations
Protein subunitPreclinical Phase
Unnamed
Generex,
EpiVax
Protein subunitPreclinical Phase
Unnamed
EpiVax,
University of Georgia
Protein subunitPreclinical Phase
PittCoVacc
University of Pittsburgh
Protein subunitPreclinical Phase
United States of America
Unnamed
University of Cambridge,
DIOSynVax
Protein subunitPreclinical Phase
UnnamedMultiple Organizations
Protein subunitPreclinical Phase
Unnamed
Sanofi Pasteur,
GSK
Protein subunitPreclinical Phase
Unnamed
Heat Biologics (Zolovax),
University of Miami
Protein subunitPreclinical Phase
UnnamedMultiple Organizations
Protein subunitPreclinical Phase
Unnamed
Baylor College of Medicine
Protein subunitPreclinical Phase
Unnamed
iBio,
CC-Pharming
Protein subunitPreclinical Phase
Unnamed
St. Petersburg Scientific Research Institute of Vaccines and Serums
Protein subunitPreclinical Phase
Unnamed
VIDO-InterVac,
University of Saskatchewan
Protein subunitPreclinical Phase
Unnamed
Flow Pharma
Protein subunitPreclinical Phase
Unnamed
OncoGen
Protein subunitPreclinical Phase
Unnamed
MIGAL Galilee Research Institute
Protein subunitPreclinical Phase
Unnamed
University of Alberta
Protein subunitPreclinical Phase
DPX-COVID-19
IMV, Inc. / Canadian Center for Vaccinology at Dalhousie University / Izaak Walton Killam Health Center/ Nova Scotia Health Authority,
Canadian Immunization Research Network / University of Laval / Global Urgent and Advanced Research and Development in Canada
Protein subunitPreclinical Phase
Canada
Unnamed
GeoVax,
BravoVax
Non-replicating viral vectorPreclinical Phase
Unnamed
Janssen Pharmaceutical Companies,
Beth Israel Deaconess Medical Center
Non-replicating viral vectorPreclinical Phase
Unnamed
ReiThera
Non-replicating viral vectorPreclinical Phase
Unnamed
ImmunityBio,
NantKwest
Non-replicating viral vectorPreclinical Phase
Unnamed
DZIF - German Center for Infection Research
Non-replicating viral vectorPreclinical Phase
AdCOVID
Altimmune,
University of Alabama at Birmingham
Non-replicating viral vectorPreclinical Phase
United States of America
Unnamed
Greffex
Non-replicating viral vectorPreclinical Phase
Unnamed
Vaxart,
Emergent BioSolutions
Non-replicating viral vectorPreclinical Phase
Unnamed
Centro Nacional Biotecnologia (CNB-CSIC),
Spain
Non-replicating viral vectorPreclinical Phase
Unnamed
University of Manitoba
Non-replicating viral vectorPreclinical Phase
Unnamed
DZIF - German Center for Infection Research
Non-replicating viral vectorPreclinical Phase
Unnamed
Tonix Pharma,
Southern Research
Non-replicating viral vectorPreclinical Phase
Unnamed
BIOCAD,
IEM
Non-replicating viral vectorPreclinical Phase
Unnamed
IAVI,
Batavia
Non-replicating viral vectorPreclinical Phase
Unnamed
The University of Hong Kong
Non-replicating viral vectorPreclinical Phase
Unnamed
University of Western Ontario
Non-replicating viral vectorPreclinical Phase
Unnamed
Valneva,
Dynavax*
Inactivated virusPreclinical Phase
Unnamed
Sinovac,
Dynavax
Inactivated virusPreclinical Phase
UnnamedMultiple Organizations
Inactivated virusPreclinical Phase
Unnamed
Codagenix,
Serum Institute of India
Inactivated virusPreclinical Phase
CoroFluMultiple Organizations
Inactivated virusPreclinical Phase
United States of AmericaRepublic of India
UnnamedMultiple Organizations
DNA-basedPreclinical Phase
Unnamed
OPENCORONA - Cobra Biologics,
Karolinska Institute
DNA-basedPreclinical Phase
UnnamedMultiple Organizations
DNA-basedPreclinical Phase
Unnamed
Zydus Cadila
DNA-basedPreclinical Phase
UnnamedMultiple Organizations
DNA-basedPreclinical Phase
Unnamed
BioNet Asia
DNA-basedPreclinical Phase
Unnamed
University of Waterloo
DNA-basedPreclinical Phase
Kasr El Aini Hospital
OtherPhase III
Egypt
NCT04357028
Immunitor LLC
Inactivated virusPhase I/II
Canada
NCT04380532
Aivita Biomedical,
Inc.
Modified APCPhase I/II
United States of America
NCT04386252
updated
Multiple Organizations
Non-replicating viral vectorPhase I/II/III
United Kingdom
NCT04324606
and 3 more
updated
Multiple Organizations
OtherPhase III/IVGlobal NCT04328441
and 14 more
new
Multiple Organizations
Inactivated virusPhase I/II
China
NCT04412538
Therapeutic Drugs
Visualized development progress and additional information on preclinical and human clinical vaccine candidates against COVID-19.
239
+9
TOTAL

92 in preclinical development

147 in human trials

Drug Candidates Development Progress

Drug CANDIDATES

Cyclosporine
Rivaroxaban
Pacritinib
Secukinumab
Tacrolimus*
Hyperbaric Chamber
Dipyridamole
AMY-101
AT-527
Fluvoxamine
CERC-002
Ulinastatin
LY3819253
DIBI
Ruconest
VIR-7831 and VIR-7832
REGN3048-3051
Polyclonal hyperimmune globulin
GP1681
SNG001
JS016
AmnioBoost
Astrostem-V
Brilacidin
+80 unnamed
Preclinical
91
Phase I
35
Phase II
107
Phase III
69
Phase IV
28

Legend

Completed
In trials
Drug CandidatesClick on name for additional information
  ↓/↑NameOrganizationTechnology  ↓/↑Stage  Countries  ↓/↑Clinical Trial #
Washington University School of Medicine
OtherPhase II
NCT04342663
University of Alabama at Birmingham
OtherPhase II
NCT04338126
and 1 more
Radboud Universit,
National University of Ireland, Galway, Ireland
OtherPhase IV
NCT04335786
and 1 more
I-Mab Biopharma Co. Ltd.
AntibodiesPhase I/II
NCT04341116
Humanigen,
Inc.
AntibodiesPhase III
NCT04351152
GlaxoSmithKline
AntibodiesPhase III
NCT04376684
Princess Nourah Bint Abdulrahman University,
MGC Pharmaceuticals
OtherPhase II
NCT04387240
and 1 more
Multiple Organizations
OtherPhase II/III/IV
NCT04355936
and 7 more
updated
Multiple Organizations
OtherPhase I/II/III/IV
NCT04261517
and 64 more
updated
Multiple Organizations
AntiviralsPhase II/III
NCT04292730
and 17 more
updated
Multiple Organizations
AntiviralsPhase I/II/III/IV
NCT04303299
and 39 more
Multiple Organizations
AntiviralsPhase III
NCT04261907
and 1 more
updated
Multiple Organizations
AntiviralsPhase II/III/IV
NCT04303299
and 20 more
Multiple Organizations
AntiviralsPhase III
ChiCTR2000029541
and 2 more
updated
Multiple Organizations
AntibodiesPhase I/II/III/IV
NCT04357808
and 13 more
updated
Multiple Organizations
AntibodiesPhase II/III/IV
NCT04317092
and 41 more
Multiple Organizations
AntibodiesPhase II/III
NCT04275414
and 3 more
Multiple Organizations
AntibodiesPhase II
NCT04268537
and 7 more
Multiple Organizations
OtherPhase II/III
NCT04268537
and 2 more
CytoDyn
AntibodiesPhase II
NCT04343651
and 2 more
Multiple Organizations
AntibodiesPhase II/III
NCT04322188
and 2 more
Multiple Organizations
AntibodiesPhase II/III
NCT04288713
and 3 more
Multiple Organizations
AntibodiesPhase II/III
NCT04362813
and 2 more
Swedish Orphan Biovitrum
AntibodiesPhase II/III
NCT04324021
Tang-Du Hospital
AntibodiesPhase I/II
NCT04275245
Eli Lilly and Company
AntibodiesPhase II
NCT04342897
Multiple Organizations
AntibodiesPhase II/III
NCT04333420
updated
Multiple Organizations
AntibodiesPhase I/II/III
NCT04321421
and 50 more
updated
Multiple Organizations
AntibodiesPhase II/III/IV
NCT04261426
and 7 more
updated
Multiple Organizations
AntiviralsPhase I/II/III/IV
NCT04303299
and 39 more
BioCryst Pharmaceuricals
AntiviralsPhase I
NCT03891420
Mianyang Central Hospital
AntiviralsPhase IV
ChiCTR2000030535
Ascletis Pharmaceuticals Co., Ltd.,
The Ninth Hospital of Nanchang
AntiviralsPhase IV
NCT04291729
Multiple Organizations
AntiviralsPhase III
ChiCTR2000029468
and 3 more
Multiple Organizations
AntiviralsPhase IV
NCT04252885
and 3 more
Roche,
The First Affiliated Hospital of Zhejiang University Medical School
AntiviralsPhase N/A
ChiCTR2000029544
and 1 more
He'nan Sincere Biotechnology Co., Ltd,

AntiviralsPhase N/A
ChiCTR2000030487
and 2 more
updated
Multiple Organizations
AntiviralsPhase III/IV
NCT04303299
and 5 more
Bausch Health Americas, Inc.,
The University of Hong Kong
AntiviralsPhase I/II
NCT04356677
and 2 more
Polyclonal hyperimmune globulinMultiple Organizations
AntibodiesPreclinical Phase
REGN3048-3051
Regeneron
AntibodiesPreclinical Phase
Unnamed
Celltrion
AntibodiesPreclinical Phase
Unnamed
Celltrion
AntibodiesPreclinical Phase
Unnamed
Kamada,
Kedrion Biopharma
AntibodiesPreclinical Phase
UnnamedMultiple Organizations
AntibodiesPreclinical Phase
VIR-7831 and VIR-7832Multiple Organizations
AntibodiesPreclinical Phase
Unnamed
Eli Lilly,
Ab-Cellera (NIH Vaccines Research Center)
AntibodiesPreclinical Phase
Bukwang Pharmaceutical
AntiviralsPhase II
NCT04347915
Athersys,
Inc.
Cell-based therapiesPhase II/III
NCT04367077
Multiple Organizations
Cell-based therapiesPhase I/II
NCT04365101
Unnamed
Erasmus MC,
Utrecht University
AntibodiesPreclinical Phase
Unnamed
ImmunoPrecise Antibodies
AntibodiesPreclinical Phase
UnnamedMultiple Organizations
AntibodiesPreclinical Phase
UnnamedMultiple Organizations
AntibodiesPreclinical Phase
Unnamed
Distributed Bio
AntibodiesPreclinical Phase
Unnamed
Chelsea and Westminster Hospital,
Imperial College London
AntibodiesPreclinical Phase
Unnamed
Vanderbilt Vaccine Center,
AstraZeneca
AntibodiesPreclinical Phase
Unnamed
Medicago,
Laval University's Infectious Disease Research Centre
AntibodiesPreclinical Phase
Unnamed
FairJourney Biologics,
Iontas
AntibodiesPreclinical Phase
Unnamed
Ligand Pharmaceuticals
AntibodiesPreclinical Phase
Unnamed
Ligand Pharmaceuticals
AntibodiesPreclinical Phase
Unnamed
Edesa Biotech,
Light Chain Bioscience (NovImmune)
AntibodiesPreclinical Phase
Unnamed
Edesa Biotech,
Light Chain Bioscience (NovImmune)
AntibodiesPreclinical Phase
Unnamed
Emergent BioSolutions,
National Institute of Allergy and Infectious Diseases (NIAID)
AntibodiesPreclinical Phase
Unnamed
Emergent BioSolutions
AntibodiesPreclinical Phase
Capricor Inc.
Cell-based therapiesPhase N/A
NCT04338347
UnnamedMultiple Organizations
AntibodiesPreclinical Phase
Unnamed
Grifols
AntibodiesPreclinical Phase
Unnamed
Grifols
AntibodiesPreclinical Phase
Unnamed
Amgen,
Adaptive Biotechnologies
AntibodiesPreclinical Phase
Unnamed
Innovent Biologics
AntibodiesPreclinical Phase
Unnamed
Xbiotech,
BioBridge Global
AntibodiesPreclinical Phase
UnnamedMultiple Organizations
AntibodiesPreclinical Phase
Unnamed
CSL Behring,
SAb Biotherapeutics
AntibodiesPreclinical Phase
Unnamed
Generation Bio,
Vir Biotechnology
AntibodiesPreclinical Phase
Unnamed
GigaGen
AntibodiesPreclinical Phase
updated
Multiple Organizations
OtherPhase II/III/IV
NCT04244591
and 14 more
Multiple Organizations
OtherPhase I/II/III/IV
NCT04321096
and 4 more
Unnamed
Public Health England (Stuart Dowall)
AntibodiesPreclinical Phase
Unnamed
ViralClear Pharmaceuticals
AntiviralsPreclinical Phase
Unnamed
Cidara Therapeutics
AntiviralsPreclinical Phase
Unnamed
ISR Immune System Regulation
AntiviralsPreclinical Phase
Unnamed
Cocrystal Pharma
AntiviralsPreclinical Phase
updated
Multiple Organizations
OtherPhase I/II/III
ChiCTR2000029580
and 16 more
UnnamedMultiple Organizations
AntiviralsPreclinical Phase
Unnamed
Agastiya Biotech*
AntiviralsPreclinical Phase
Unnamed
Pluristem Ltd.
Cell-based therapiesPreclinical Phase
Unnamed
Celltex
Cell-based therapiesPreclinical Phase
Mesoblast, Inc,
Icahn School of Medicine at Mount Sinai
Cell-based therapiesPhase III
NCT04371393
and 1 more
Multiple Organizations
OtherPhase IV
ChiCTR2000029573
and 1 more
Unnamed
AlloVir,
Baylor College of Medicine
Cell-based therapiesPreclinical Phase
Unnamed
GC LabCell,
KLEO Pharmaceuticals
Cell-based therapiesPreclinical Phase
Unnamed
ImmunityBio,
NantKwest
Cell-based therapiesPreclinical Phase
Unnamed
ImmunityBio,
NantKwest
Cell-based therapiesPreclinical Phase
Astrostem-V
Naturecell*
Cell-based therapiesPreclinical Phase
AmnioBoost
Lattice Biologics*
Cell-based therapiesPreclinical Phase
Unnamed
Sirnaomics
RNA-based treatmentsPreclinical Phase
Unnamed
Vir Biotech,
Alnylam Pharmaceuticals
RNA-based treatmentsPreclinical Phase
Unnamed
AIM ImmunoTech,
National Institute of Infectious Diseases in Japan
RNA-based treatmentsPreclinical Phase
Unnamed
Mateon Therapeutics
RNA-based treatmentsPreclinical Phase
Unnamed
Neurimmune,
Ethris
RNA-based treatmentsPreclinical Phase
Unnamed
Janssen Pharmaceutical Companies
Scanning Compounds to RepurposePreclinical Phase
Unnamed
Novartis
Scanning Compounds to RepurposePreclinical Phase
Unnamed
Pfizer
Scanning Compounds to RepurposePreclinical Phase
Unnamed
Merck
Scanning Compounds to RepurposePreclinical Phase
Unnamed
Materia Medica,
Cyclica
Scanning Compounds to RepurposePreclinical Phase
Unnamed
Enanta Pharmaceuticals
Scanning Compounds to RepurposePreclinical Phase
Unnamed
Southwest Research Institute
Scanning Compounds to RepurposePreclinical Phase
Unnamed
Takeda
Scanning Compounds to RepurposePreclinical Phase
Unnamed
Queens University Belfast
Scanning Compounds to RepurposePreclinical Phase
UnnamedMultiple Organizations
Scanning Compounds to RepurposePreclinical Phase
Unnamed
Healx
Scanning Compounds to RepurposePreclinical Phase
Unnamed
The Castleman Disease Collaborative Network and the Center for Study & Treatment of Inflammatory Lymphadenopathies
Scanning Compounds to RepurposePreclinical Phase
Unnamed
Anixa Biosciences,
OntoChem
Scanning Compounds to RepurposePreclinical Phase
UnnamedMultiple Organizations
Scanning Compounds to RepurposePreclinical Phase
Unnamed
Nuritas*
Scanning Compounds to RepurposePreclinical Phase
Multiple Organizations
OtherPhase III/IV
NCT04320238
and 1 more
Unnamed
Zydus Cadila Group,
Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital) (Schering)*
OtherPreclinical Phase
SNG001
Synairgen,
University of Southampton
OtherPreclinical Phase
Algernon Pharmaceuticals,
Novotech
OtherPhase II/III
NCT04382924
Apeiron Biologics
OtherPhase II
NCT04335136
Brilacidin
Innovation Pharmaceuticals
OtherPreclinical Phase
Unnamed
Bioxytran
OtherPreclinical Phase
The First Affiliated Hospital of Fujian Medical University,
Novartis
OtherPhase II
NCT04280588
Unnamed
CEL-SCI,
University of Georgia Center for Vaccines and Immunology
OtherPreclinical Phase
Unnamed
Biomarck Pharmaceuticals
OtherPreclinical Phase
Multiple Organizations
OtherPhase II/III
NCT04352400
Unnamed
Moleculin Biotech,
University of Texas Medical Branch
OtherPreclinical Phase
Multiple Organizations
OtherPhase I/II/III
NCT04312009
and 5 more
Unnamed
NanoViricides
OtherPreclinical Phase
University College, London,
Denver Health and Hospital Authority
OtherPhase II
University College, London; Denver Health and Hospital Authority; Genentech, Inc.
updated
Multiple Organizations
OtherPhase II/IV
NCT04326920
and 3 more
updated
Multiple Organizations
OtherPhase II/III/IV
NCT04324021
and 21 more
NYU Langone Health
OtherPhase II
NCT04365699
BioAegis Therapeutics Inc.
OtherPhase II
NCT04358406
PharmaMar,
Apices Soluciones S.L.
OtherPhase I
NCT04382066
Multiple Organizations
OtherPhase I/II/III
NCT04305457
and 12 more
Medical University of Vienna,
Apeptico
OtherPhase II
EudraCT 2020-001244-26
Pulmotect,
Inc.
OtherPhase II
NCT04312997
and 1 more
Unnamed
Panoptes Pharma GmbH
OtherPreclinical Phase
UnnamedMultiple Organizations
OtherPreclinical Phase
updated
Pfizer,
Università Politecnica delle Marche
OtherPhase II
NCT04332042
and 1 more
Multiple Organizations
OtherPhase II/III
NCT04350320
and 10 more
Karyopharm Therapeutics
OtherPhase II
NCT04355676
and 2 more
Unnamed
Laurent Pharmaceuticals
OtherPreclinical Phase
Blade Therapeutics
OtherPhase II
NCT04334460
Multiple Organizations
OtherPhase II
NCT04346199
and 2 more
OncoImmune,
Inc.
OtherPhase III
NCT04317040
Multiple Organizations
OtherPhase II/III
NCT04311697
and 1 more
Biohaven Pharmaceuticals,
Inc.
OtherPhase II/III
NCT04346615
CalciMedica,
Inc.
OtherPhase II
NCT04345614
Multiple Organizations
OtherPhase I/II/III
NCT04343092
and 12 more
Multiple Organizations
OtherPhase II/III/IV
NCT04351347
and 8 more
updated
Multiple Organizations
OtherPhase II/III
NCT04335032
and 1 more
Multiple Organizations
OtherPhase II/III
NCT04345419
and 2 more
Can-Fite BioPharma
OtherPhase II
NCT04333472
Unnamed
Aldeyra Therapeutics
OtherPreclinical Phase
ImmunityBio,
Inc.
OtherPhase I
NCT04385849
4D pharma plc
OtherPhase II
NCT04363372
UnnamedMultiple Organizations
OtherPreclinical Phase
Unnamed
Noxopharm*
OtherPreclinical Phase
Multiple Organizations
OtherPhase II/III
NCT04350593
and 1 more
Unnamed
Cyclacel Pharmaceuticals,
University of Edinburgh*
OtherPreclinical Phase
Unnamed
Cyclacel Pharmaceuticals,
University of Edinburgh*
OtherPreclinical Phase
updated
aTyr Pharma,
Inc.
OtherPhase II
NCT04412668
Ruconest
Pharming*
OtherPreclinical Phase
Multiple Organizations
DevicePhase N/A
NCT04324528
and 2 more
Bellerophon,
University of Miami
DevicePhase II
NCT04358588
and 1 more
Unnamed
Terumo BCT Inc,
Marker Therapeutics AG
DevicePreclinical Phase
Marker Therapeutics AG
DevicePhase N/A
NCT04358003
Unnamed
ExThera Medical
DevicePreclinical Phase
Unnamed
Baxter
DevicePreclinical Phase
Shanghai Public Health Clinical Center,
Zhongnan Hospital of Wuhan University
AntiviralsPhase III
ChiCTR2000029541
and 1 more
Chongqing Public Health Medical Center,
Chongqing Sidemu Biotechnology Technology Co.,Ltd.
Cell-based therapiesPhase I/II
NCT04324996
Millennium Pharmaceuticals,
Inc.
OtherPhase I
NCT03648372
Multiple Organizations
OtherPhase I/II
NCT04343768
and 3 more
Multiple Organizations
OtherPhase II/III
NCT04346147
and 3 more
Imperial College London,
ACOVACT
OtherPhase II/III
NCT04351724
and 1 more
JS016
Junshi Biosciences,
Eli Lilly
AntibodiesPreclinical Phase
Roswell Park Cancer Institute,
National Cancer Institute (NCI)
RNA-based treatmentsPhase I/II
NCT04379518
Vanda Pharmaceuticals
OtherPhase III
NCT04326426
Innate Pharma,
Assistance Publique Hopitaux De Marseille
AntibodiesPhase II
NCT04371367
updated
Multiple Organizations
OtherPhase I/II/III/IV
NCT02735707
and 19 more
DIBI
Chelation Partners
OtherPreclinical Phase
Insmed Inc.,
University of Dundee
OtherPhase III
EudraCT 2020-001643-13
Ansun Biopharma, Inc.,
Renmin Hospital of Wuhan University
AntiviralsPhase N/A
NCT04324489
GP1681
Quotient Sciences,
CytoAgents
OtherPreclinical Phase
Arch Biopartners
OtherPhase II
Pacritinib
CTI Biopharma
OtherPhase III
NCT04404361
Kinevant Sciences GmbH,
Roivant Sciences, Inc.
AntibodiesPhase II
NCT04351243
Alexion Pharmaceuticals,
Cambridge University Hospitals NHS Foundation Trust
AntibodiesPhase III/IV
NCT04369469
and 1 more
Implicit Bioscience,
University of Washington
AntibodiesPhase II
NCT04346277
and 1 more